Date Filed | Type | Description |
10/13/2023 |
8-K
| Quarterly results |
10/04/2023 |
SC 13D/A
| Morningside Venture Investments Ltd reports a 3.4% stake in Amylyx Pharmaceuticals, Inc. |
08/17/2023 |
SC 13D/A
| Morningside Venture Investments Ltd reports a 6.9% stake in Amylyx Pharmaceuticals, Inc. |
08/15/2023 |
144
| Form 144 - Report of proposed sale of securities: |
08/10/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
08/10/2023 |
8-K
| Quarterly results |
07/26/2023 |
8-K
| Quarterly results |
06/09/2023 |
SC 13G
| GOLDMAN SACHS GROUP INC reports a 5.4% stake in AMYLYX PHARMACEUTICALS, INC. |
06/09/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
05/16/2023 |
144
| Form 144 - Report of proposed sale of securities: |
05/15/2023 |
144
| Form 144 - Report of proposed sale of securities: |
05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
05/11/2023 |
8-K
| Quarterly results |
04/27/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
04/27/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
04/17/2023 |
144
| Form 144 - Report of proposed sale of securities: |
04/03/2023 |
SC 13D/A
| Morningside Venture Investments Ltd reports a 12.9% stake in Amylyx Pharmaceuticals, Inc. |
03/21/2023 |
8-K
| Appointed a new director |
03/16/2023 |
144
| Form 144 - Report of proposed sale of securities: |
03/16/2023 |
144
| Form 144 - Report of proposed sale of securities: |
03/16/2023 |
144
| Form 144 - Report of proposed sale of securities: |
03/16/2023 |
144
| Form 144 - Report of proposed sale of securities: |
03/16/2023 |
144
| Form 144 - Report of proposed sale of securities: |
03/13/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
03/13/2023 |
S-3ASR
| Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers: |
03/13/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
03/13/2023 |
8-K
| Quarterly results |
02/14/2023 |
SC 13G/A
| PERCEPTIVE ADVISORS LLC reports a 9.2% stake in Amylyx Pharmaceuticals, Inc. |
02/14/2023 |
SC 13G/A
| VIKING GLOBAL INVESTORS LP reports a 7% stake in Amylyx Pharmaceuticals, Inc. |
02/14/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
02/13/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
02/09/2023 |
SC 13G
| VANGUARD GROUP INC reports a 6.6% stake in Amylyx Pharmaceuticals Inc. |
01/11/2023 |
5
| Morningside Venture Investments Ltd (10% Owner) has filed a Form 5 on Amylyx Pharmaceuticals, Inc. |
|